3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Squamous Cell
2
Carcinoma, Non-Small-Cell Lung
2
Tongue Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Klatskin Tumor
1
Head and Neck Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Large Cell
1
Adenocarcinoma
1
Interventions
Gemcitabine
82
Cisplatin
52
Oxaliplatin
36
lenvatinib
24
durvalumab
22
Capecitabine
22
Fluorouracil
20
Leucovorin
15
tislelizumab
11
pembrolizumab
10
apatinib
10
Radiotherapy
10
Albumin-Bound Paclitaxel
10
Radiofrequency Ablation
9
Magnetic Resonance Spectroscopy
9
Irinotecan
9
Floxuridine
9
Liver Transplantation
8
Drug Therapy
8
Cholangiopancreatography, Endoscopic Retrograde
8
130-nm albumin-bound paclitaxel
8
Taxes
7
Platinum
7
Photochemotherapy
7
Panitumumab
7
Biopsy
7
1,2-diaminocyclohexaneplatinum II citrate
7
tremelimumab
6
pemigatinib
6
camrelizumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cholangiocarcinoma
×
temoporfin
×
Clear all
NCT03003065
2023-08-22
PDT
Chinese University of Hong Kong
Phase 2
Completed
10 enrolled